Regeneron Finalizes Praluent Agreement Restructuring
06 Abril 2020 - 8:42PM
Dow Jones News
By Stephen Nakrosis
Regeneron Pharmaceuticals, Inc. on Monday said it finalized a
restructuring of its Praluent agreements with Sanofi.
The company said the restructured agreements, which were
effective April 1, call for Regeneron to have sole responsibility
for Praluent and record net product sales in the U.S. Sanofi will
have sole responsibility outside the U.S. and pay Regeneron a
royalty on Praluent net product sales, the company said.
Praluent is indicated to reduce the risk of myocardial
infarction, stroke, and unstable angina requiring hospitalization
in adults with established cardiovascular disease, and also for the
treatment of adults with primary hyperlipidemia to reduce
low-density lipoprotein cholesterol, Regeneron said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 06, 2020 19:27 ET (23:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
